Induction of heat shock protein gp96 by immune cytokines

Cell Stress and Chaperones

Volumn 8, Issue 3, 2003, Pages 242-248

  Chen, Y G ^a   Ashok, B T ^a   Liu, X ^a   Garikapaty, V P S ^a   Mittelman, A ^a   Tiwari, Raj K ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA BINDING PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN; INTERLEUKIN 2; STAT1 PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA BINDING; DRUG EFFECT; GENE EXPRESSION; KIDNEY EPITHELIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; TRANS-ACTIVATION (GENETICS);

ANIMALIA;

EID: 0345306711     PISSN: 13558145     EISSN: None     Source Type: Journal    
DOI: 10.1379/1466-1268(2003)008<0242:IOHSPG>2.0.CO;2     Document Type: Article

References (53)

1. Anderson SL, Shen T, Lou J, Xing L, Blachere NE, Srivastava PK, Rubin BY. 1994. The endoplasmic reticular heat shock protein gp96 is transcriptionally upregulated in interferon-treated cells. J Exp Med 180: 1565-1569.
2. Arnold D, Driscoll J, Androlewicz M, Hughes E, Cresswell P, Spies T. 1992. Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules. Nature 360: 171-174.
3. Arnold D, Wahl C, Faath S, Rammensee HG, Schild H. 1997. Influences of transporter associated with antigen processing (TAP) on the repertoire of peptides associated with the endoplasmic reticulum-resident stress protein gp96. J Exp Med 186: 461-466.
4. Ashok BT, Chen YG, Liu X, et al. 2002. Multiple molecular targets of indole-3-carbinol, a chemopreventive anti-estrogen in breast cancer. Eur J Cancer Prev 11: S86-S93.
5. Ashok BT, Kim E, Mittelman A, Tiwari RK. 2001. Proteasome inhibitors differentially affect heat shock protein response in cancer cells. Int J Mol Med 8: 385-390.
6. Bader T, Weitzerbin J. 1994. Nuclear accumulation of interferon gamma. Proc Natl Acad Sci U S A 91: 11831-11835.
7. Banerjee PP, Vinay DS, Mathew A, et al. 2002. Evidence that glycoprotein 96 (b2), a stress protein, functions as a Th2-specific costimulatory molecule. J Immunol 169: 3507-3518.
8. Binder RJ, Han DK, Srivastava PK, 2000a. CD91: a receptor for heat shock protein gp96. Nat Immunol 1: 151-155.
9. Binder RJ, Harris ML, Menoret A, Srivastava PK. 2000b. Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells. J Immunol 165: 2582-2587.
10. Bromberg J, Darnell JE Jr. 2000. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473.
11. Bromberg JF, Darnell JE Jr. 1999. Potential roles of Stat1 and Stat3 in cellular transformation. Cold Spring Harbor Symp Quant Biol 64: 425-428.
12. Caudill MM, Li Z. 2001. HSPPC-96: a personalised cancer vaccine. Expert Opin Biol Ther 1: 539-547.
13. Costello RT, Gastaut JA, Olive D. 1999. Mechanisms of tumor escape from immunologic response. Rev Med Interne 20: 579-588.
14. Cousins DJ, Lee TH, Staynov DZ. 2002. Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression of Th2 cytokines. J Immunol 169: 2498-2506.
15. Cresswell P, Bangia N, Dick T, Diedrich G. 1999. The nature of the MHC class I peptide loading complex. Immunol Rev 172: 21-28.
16. Cresswell P, Lanzavecchia A. 2001. Antigen processing and recognition. Curr Opin Immunol 13: 11-12.
17. Darniani G, Capelli E, Comincini S, Mori E, Panelli S, Cuccia M. 1998. Identification of mRNAs differentially expressed in lymphocytes following interleukin-2 activation. Exp Cell Res 245: 27-33.
18. Darnell JE Jr. 1997. STATs and gene regulation. Science 277: 1630-1635.
19. Flores I, Casaseca T, Martinez A, Kanoh H, Merida I. 1996. Phosphatidic acid generation through interleukin 2 (IL-2)-induced alpha-diacylglycerol kinase activation is an essential step in IL-2-mediated lymphocyte proliferation. J Biol Chem 271: 10334-10340.
20. Forni G, Boggio K, Giovarelli M, Cavallo F. 1997. The dream of effective cytokine-based tumor vaccines. Eur Cytokine Netw 8: 324-325.
21. Gilboa E. 1999. How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 48: 382-385.
22. Greten TF, Jaffee EM. 1999. Cancer vaccines. J Clin Oncol 17: 1047-1060.
23. Guo FH, Uetani K, Haque SJ, Williams BR, Dweik RA, Thunnissen FB, Calhoun W, Erzurum SC. 1997. Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J Clin Investig 100: 829-838.
24. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. 2000. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 88: 232-238.
25. Kang JK, Yoon SJ, Kim NK, Heo DS. 2000. The expression of MHC class I, TAP1/2, and LMP2/7 gene in human gastric cancer cell lines. Int J Oncol 16: 1159-1163.
26. Kaplan G. 1993. Recent advances in cytokine therapy in leprosy. J Infect Dis 167(Suppl 1): S18-S22.
27. Kobayashi K, Kai M, Gidoh M, Nakata N, Endoh M, Singh RP, Kasama T, Saito H. 1998. The possible role of interleukin (IL)-12 and interferon-gamma-inducing factor/IL-18 in protection against experimental Mycobacterium leprae infection in mice. Clin Immunol Immunopathol 88: 226-231.
28. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
29. Lammert E, Arnold D, Nijenhuis M, et al. 1997. The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur J Immunol 27: 923-927.
30. Linderoth NA, Simon MN, Hainfeld JF, Sastry S. 2001. Binding of antigenic peptide to the endoplasmic reticulum-resident protein gp96/GRP94 heat shock chaperone occurs in higher order complexes. Essential role of some aromatic amino acid residues in the peptide-binding site. J Biol Chem 276: 11049-11054.
31. Makrigiannis AP, Pau AT, Saleh A, Winkler-Pickett R, Ortaldo JR, Anderson SK. 2001. Class I MHC-binding characteristics of the 129/J Ly49 repertoire. J Immunol 166: 5034-5043.
32. Ohh M, Takei F. 1996. New insights into the regulation of ICAM-1 gene expression. Leuk Lymphoma 20: 223-228.
33. Overwijk WW, Theoret MR, Restifo NP. 2000. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am 6(Suppl 1): S76-S80.
34. Przepiorka D, Srivastava PK. 1998. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol Med Today 4: 478-484.
35. Ramana CV, Chatterjee-Kishore M, Nguyen H, Stark GR. 2000a. Complex roles of Stat1 in regulating gene expression. Oncogene 19: 2619-2627.
36. Ramana CV, Grammatikakis N, Chernov M, Nguyen H, Goh KC, Williams BR, Stark GR. 2000b. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J 19: 263-272.
37. Rosenberg SA. 2001. Progress in human tumour immunology and immunotherapy. Nature 411: 380-384.
38. Sastry S, Linderoth N. 1999. Molecular mechanisms of peptide loading by the tumor rejection antigen/heat shock chaperone gp96 (GRP94). J Biol Chem 274: 12023-12035.
39. Seliger B, Cabrera T, Garrido F, Ferrone S. 2002. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12: 3-13.
40. Seliger B, Maeurer MJ, Ferrone S. 2000. Antigen-processing machinery breakdown and tumor growth. Immunol Today 21: 455-464.
41. Shuai K. 2000. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 19: 2638-2644.
42. Spee P, Neefjes J. 1997. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol 27: 2441-2449.
43. Srivastava P. 2002a. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20: 395-425.
44. Srivastava P. 2002b. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2: 185-194.
45. Srivastava PK. 2001. A central role for heat shock proteins in host deficiency. Adv Exp Med Biol 495: 121-126.
46. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. 1998. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8: 657-665.
47. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu Rev Biochem 67: 227-264.
48. Suto R, Srivastava PK. 1995. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269: 1585-1588.
49. Swannie HC, Kaye SB. 2002. Protein kinase C inhibitors. Curr Oncol Rep 4: 37-46.
50. Velders MP, Schreiber H, Kast WM. 1998. Active immunization against cancer cells: impediments and advances. Semin Oncol 25: 697-706.
51. Yedavelli SP, Guo L, Daou ME, Srivastava PK, Mittelman A, Tiwari RK. 1999. Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Int J Mol Med 4: 243-248.
52. Yewdell J, Lapham C, Bacik I, Spies T, Bennink J. 1994. MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. J Immunol 152: 1163-1170.
53. Zheng P, Sarma S, Guo Y, Liu Y. 1999. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res 59: 3461-3467.